Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$7.06 ▼ -0.38
(-5.11%)
MKT CAP: $205.4M • VOL: 108.9K
52W L $4 52W H $10
DTIL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $34.3M | $68.7M | $48.7M |
| YoY Revenue Growth % | -50.1% | +41.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$52.1M | -$26.2M | -$43.7M |
| Operating Margin % | -80.0% | -38.1% | -80.0% |
| Net Income (GAAP) | -$45.7M | $7.2M | -$61.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$65.8M | -$58.4M | -$84.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$65.8M | -$58.4M | -$84.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $110.8M | $85.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $92.2M | $56.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DTIL.